255 related articles for article (PubMed ID: 33431610)
1. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
[TBL] [Abstract][Full Text] [Related]
2. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
3. Safety and Tolerability of GalNAc
Baker BF; Xia S; Partridge W; Engelhardt JA; Tsimikas S; Crooke ST; Bhanot S; Geary RS
Nucleic Acid Ther; 2024 Feb; 34(1):18-25. PubMed ID: 38227794
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc
Wang Y; Yu RZ; Henry S; Geary RS
Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):475-485. PubMed ID: 31144994
[No Abstract] [Full Text] [Related]
5. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
[TBL] [Abstract][Full Text] [Related]
6. Integrated Assessment of Phase 2 Data on GalNAc
Baker BF; Xia S; Partridge W; Kwoh TJ; Tsimikas S; Bhanot S; Geary RS
Nucleic Acid Ther; 2023 Jan; 33(1):72-80. PubMed ID: 36454263
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP
Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the Drug Interaction Potential of Unconjugated and GalNAc
Shemesh CS; Yu RZ; Warren MS; Liu M; Jahic M; Nichols B; Post N; Lin S; Norris DA; Hurh E; Huang J; Watanabe T; Henry SP; Wang Y
Mol Ther Nucleic Acids; 2017 Dec; 9():34-47. PubMed ID: 29246313
[TBL] [Abstract][Full Text] [Related]
9. Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice.
Yu RZ; Graham MJ; Post N; Riney S; Zanardi T; Hall S; Burkey J; Shemesh CS; Prakash TP; Seth PP; Swayze EE; Geary RS; Wang Y; Henry S
Mol Ther Nucleic Acids; 2016 May; 5(5):e317. PubMed ID: 27138177
[TBL] [Abstract][Full Text] [Related]
10. Interspecies Scaling of Human Clearance and Plasma Trough Exposure for Antisense Oligonucleotides: A Retrospective Analysis of GalNAc3-Conjugated and Unconjugated-Antisense Oligonucleotides.
Nanavati C; McMullen G; Yu R; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2021 Aug; 31(4):298-308. PubMed ID: 33891483
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the Effects of 2'-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates.
Henry SP; Narayanan P; Shen L; Bhanot S; Younis HS; Burel SA
Nucleic Acid Ther; 2017 Aug; 27(4):197-208. PubMed ID: 28541820
[TBL] [Abstract][Full Text] [Related]
12. Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon response.
Burel SA; Machemer T; Ragone FL; Kato H; Cauntay P; Greenlee S; Salim A; Gaarde WA; Hung G; Peralta R; Freier SM; Henry SP
J Pharmacol Exp Ther; 2012 Jul; 342(1):150-62. PubMed ID: 22505629
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
[TBL] [Abstract][Full Text] [Related]
14. Chronic Toxicity Assessment of 2'-O-Methoxyethyl Antisense Oligonucleotides in Mice.
Zanardi TA; Kim TW; Shen L; Serota D; Papagiannis C; Park SY; Kim Y; Henry SP
Nucleic Acid Ther; 2018 Aug; 28(4):233-241. PubMed ID: 29708844
[TBL] [Abstract][Full Text] [Related]
15. Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys.
Shemesh CS; Yu RZ; Gaus HJ; Greenlee S; Post N; Schmidt K; Migawa MT; Seth PP; Zanardi TA; Prakash TP; Swayze EE; Henry SP; Wang Y
Mol Ther Nucleic Acids; 2016 May; 5(5):e319. PubMed ID: 27164023
[TBL] [Abstract][Full Text] [Related]
16. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease.
Donner AJ; Bell TA; Greenlee S; Graham MJ; Crooke RM
Nucleic Acid Ther; 2018 Oct; 28(5):297-306. PubMed ID: 30133341
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals.
Swayze EE; Siwkowski AM; Wancewicz EV; Migawa MT; Wyrzykiewicz TK; Hung G; Monia BP; Bennett CF
Nucleic Acids Res; 2007; 35(2):687-700. PubMed ID: 17182632
[TBL] [Abstract][Full Text] [Related]
19. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes.
Tanowitz M; Hettrick L; Revenko A; Kinberger GA; Prakash TP; Seth PP
Nucleic Acids Res; 2017 Dec; 45(21):12388-12400. PubMed ID: 29069408
[TBL] [Abstract][Full Text] [Related]
20. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
